Anti-MSPD3/ MOSPD3/ CDS3 monoclonal antibody

Anti-MSPD3/ MOSPD3/ CDS3 antibody for FACS & in-vivo assay

Target products collectionGo to MOSPD3/MOSPD3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0821-Ab-1/ GM-Tg-hg-MP0821-Ab-2Anti-Human MOSPD3 monoclonal antibodyHuman
GM-Tg-rg-MP0821-Ab-1/ GM-Tg-rg-MP0821-Ab-2Anti-Rat MOSPD3 monoclonal antibodyRat
GM-Tg-mg-MP0821-Ab-1/ GM-Tg-mg-MP0821-Ab-2Anti-Mouse MOSPD3 monoclonal antibodyMouse
GM-Tg-cynog-MP0821-Ab-1/ GM-Tg-cynog-MP0821-Ab-2Anti-Cynomolgus/ Rhesus macaque MOSPD3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0821-Ab-1/ GM-Tg-felg-MP0821-Ab-2Anti-Feline MOSPD3 monoclonal antibodyFeline
GM-Tg-cang-MP0821-Ab-1/ GM-Tg-cang-MP0821-Ab-2Anti-Canine MOSPD3 monoclonal antibodyCanine
GM-Tg-bovg-MP0821-Ab-1/ GM-Tg-bovg-MP0821-Ab-2Anti-Bovine MOSPD3 monoclonal antibodyBovine
GM-Tg-equg-MP0821-Ab-1/ GM-Tg-equg-MP0821-Ab-2Anti-Equine MOSPD3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0821-Ab-1/ GM-Tg-hg-MP0821-Ab-2; GM-Tg-rg-MP0821-Ab-1/ GM-Tg-rg-MP0821-Ab-2;
GM-Tg-mg-MP0821-Ab-1/ GM-Tg-mg-MP0821-Ab-2; GM-Tg-cynog-MP0821-Ab-1/ GM-Tg-cynog-MP0821-Ab-2;
GM-Tg-felg-MP0821-Ab-1/ GM-Tg-felg-MP0821-Ab-2; GM-Tg-cang-MP0821-Ab-1/ GM-Tg-cang-MP0821-Ab-2;
GM-Tg-bovg-MP0821-Ab-1/ GM-Tg-bovg-MP0821-Ab-2; GM-Tg-equg-MP0821-Ab-1/ GM-Tg-equg-MP0821-Ab-2
Products NameAnti-MOSPD3 monoclonal antibody
Formatmab
Target NameMOSPD3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MOSPD3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species MSPD3/ MOSPD3/ CDS3 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0821
    Target NameMOSPD3
    Gene ID64598,68929,288557,712566,608423,101092224,506163,100067442
    Gene Symbol and Synonyms1190005J19Rik,5133401H10Rik,CDS3,Gtig2,MOSPD3,NET30,R124
    Uniprot AccessionO75425,Q3T033
    Uniprot Entry NameMSPD3_HUMAN,MSPD3_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000106330
    Target ClassificationN/A

    The target: MOSPD3, gene name: MOSPD3, also named as CDS3, NET30. This gene encodes a multi-pass membrane protein with a major sperm protein (MSP) domain. The deletion of a similar mouse gene is associated with defective cardiac development and neonatal lethality. Alternate transcriptional splice variants, encoding different isoforms, have been described. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.